A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort

Terry, Kathryn L.; Schock, Helena; Fortner, Renée T.; Hüsing, Anika; Fichorova, Raina N.; Yamamoto, Hidemi S.; Vitonis, Allison F.; Johnson, Theron; Overvad, Kim; Tjønneland, Anne; Boutron-Ruault, Marie-Christine; Mesrine, Sylvie; Severi, Gianluca; Dossus, Laure; Rinaldi, Sabina; Boeing, Heiner; Benetou, Vassiliki; Lagiou, Pagona; Trichopoulou, Antonia; Krogh, Vittorio; Kuhn, Elisabetta; Panico, Salvatore; Bueno de Mesquita, H. Bas; Onland-Moret, N. Charlotte; Peeters, Petra H. M.; Torhild Gram, Inger; Weiderpass, Elisabete; Duell, Eric J.; Sánchez, María José; Ardanaz, Eva; Etxezarreta, Nerea; Navarro, Carmen; Idahl, Annika; Lundin, Eva; Jirström, Karin; Manjer, Jonas; Wareham, Nicholas J.; Khaw, Kay-Tee; Smith-Byrne, Karl; Travis, Ruth C.; Gunter, Marc J.; Merritt, Melissa A.; Riboli, Elio; Cramer, Daniel W.; Kaaks, Rudolf

A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort

Purpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best so...

Descripción completa

Detalles Bibliográficos
Autores:	Terry, Kathryn L., Schock, Helena, Fortner, Renée T., Hüsing, Anika, Fichorova, Raina N., Yamamoto, Hidemi S., Vitonis, Allison F., Johnson, Theron, Overvad, Kim, Tjønneland, Anne, Boutron-Ruault, Marie-Christine, Mesrine, Sylvie, Severi, Gianluca, Dossus, Laure, Rinaldi, Sabina, Boeing, Heiner, Benetou, Vassiliki, Lagiou, Pagona, Trichopoulou, Antonia, Krogh, Vittorio, Kuhn, Elisabetta, Panico, Salvatore, Bueno de Mesquita, H. Bas, Onland-Moret, N. Charlotte, Peeters, Petra H. M., Torhild Gram, Inger, Weiderpass, Elisabete, Duell, Eric J., Sánchez, María José, Ardanaz, Eva, Etxezarreta, Nerea, Navarro, Carmen, Idahl, Annika, Lundin, Eva, Jirström, Karin, Manjer, Jonas, Wareham, Nicholas J., Khaw, Kay-Tee, Smith-Byrne, Karl, Travis, Ruth C., Gunter, Marc J., Merritt, Melissa A., Riboli, Elio, Cramer, Daniel W., Kaaks, Rudolf
Tipo de recurso:	artículo
Estado:	Versión aceptada para publicación
Fecha de publicación:	2016
País:	España
Institución:	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:	Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:	oai:recercat.cat:2445/125704
Acceso en línea:	https://hdl.handle.net/2445/125704
Access Level:	acceso abierto
Palabra clave:	Càncer d'ovari Marcadors bioquímics Ovarian cancer Biochemical markers

id	ES_e8a3accfa0323548cc5f736168178d5f
oai_identifier_str	oai:recercat.cat:2445/125704
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohortTerry, Kathryn L.Schock, HelenaFortner, Renée T.Hüsing, AnikaFichorova, Raina N.Yamamoto, Hidemi S.Vitonis, Allison F.Johnson, TheronOvervad, KimTjønneland, AnneBoutron-Ruault, Marie-ChristineMesrine, SylvieSeveri, GianlucaDossus, LaureRinaldi, SabinaBoeing, HeinerBenetou, VassilikiLagiou, PagonaTrichopoulou, AntoniaKrogh, VittorioKuhn, ElisabettaPanico, SalvatoreBueno de Mesquita, H. BasOnland-Moret, N. CharlottePeeters, Petra H. M.Torhild Gram, IngerWeiderpass, ElisabeteDuell, Eric J.Sánchez, María JoséArdanaz, EvaEtxezarreta, NereaNavarro, CarmenIdahl, AnnikaLundin, EvaJirström, KarinManjer, JonasWareham, Nicholas J.Khaw, Kay-TeeSmith-Byrne, KarlTravis, Ruth C.Gunter, Marc J.Merritt, Melissa A.Riboli, ElioCramer, Daniel W.Kaaks, RudolfCàncer d'ovariMarcadors bioquímicsOvarian cancerBiochemical markersPurpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate earlydetection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study. Experimental Design: We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. Results: We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. Conclusions: CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases. (C) 2016 AACR.American Association for Cancer Research2018201820162018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion23 p.application/pdfhttps://hdl.handle.net/2445/125704Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1158/1078-0432.CCR-16-0316Clinical Cancer Research, 2016, vol. 22, num. 18, p. 4664-4675https://doi.org/10.1158/1078-0432.CCR-16-0316(c) American Association for Cancer Research, 2016info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1257042026-05-29T05:05:01Z
dc.title.none.fl_str_mv	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
title	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
spellingShingle	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort Terry, Kathryn L. Càncer d'ovari Marcadors bioquímics Ovarian cancer Biochemical markers
title_short	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
title_full	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
title_fullStr	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
title_full_unstemmed	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
title_sort	A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort
dc.creator.none.fl_str_mv	Terry, Kathryn L. Schock, Helena Fortner, Renée T. Hüsing, Anika Fichorova, Raina N. Yamamoto, Hidemi S. Vitonis, Allison F. Johnson, Theron Overvad, Kim Tjønneland, Anne Boutron-Ruault, Marie-Christine Mesrine, Sylvie Severi, Gianluca Dossus, Laure Rinaldi, Sabina Boeing, Heiner Benetou, Vassiliki Lagiou, Pagona Trichopoulou, Antonia Krogh, Vittorio Kuhn, Elisabetta Panico, Salvatore Bueno de Mesquita, H. Bas Onland-Moret, N. Charlotte Peeters, Petra H. M. Torhild Gram, Inger Weiderpass, Elisabete Duell, Eric J. Sánchez, María José Ardanaz, Eva Etxezarreta, Nerea Navarro, Carmen Idahl, Annika Lundin, Eva Jirström, Karin Manjer, Jonas Wareham, Nicholas J. Khaw, Kay-Tee Smith-Byrne, Karl Travis, Ruth C. Gunter, Marc J. Merritt, Melissa A. Riboli, Elio Cramer, Daniel W. Kaaks, Rudolf
author	Terry, Kathryn L.
author_facet	Terry, Kathryn L. Schock, Helena Fortner, Renée T. Hüsing, Anika Fichorova, Raina N. Yamamoto, Hidemi S. Vitonis, Allison F. Johnson, Theron Overvad, Kim Tjønneland, Anne Boutron-Ruault, Marie-Christine Mesrine, Sylvie Severi, Gianluca Dossus, Laure Rinaldi, Sabina Boeing, Heiner Benetou, Vassiliki Lagiou, Pagona Trichopoulou, Antonia Krogh, Vittorio Kuhn, Elisabetta Panico, Salvatore Bueno de Mesquita, H. Bas Onland-Moret, N. Charlotte Peeters, Petra H. M. Torhild Gram, Inger Weiderpass, Elisabete Duell, Eric J. Sánchez, María José Ardanaz, Eva Etxezarreta, Nerea Navarro, Carmen Idahl, Annika Lundin, Eva Jirström, Karin Manjer, Jonas Wareham, Nicholas J. Khaw, Kay-Tee Smith-Byrne, Karl Travis, Ruth C. Gunter, Marc J. Merritt, Melissa A. Riboli, Elio Cramer, Daniel W. Kaaks, Rudolf
author_role	author
author2	Schock, Helena Fortner, Renée T. Hüsing, Anika Fichorova, Raina N. Yamamoto, Hidemi S. Vitonis, Allison F. Johnson, Theron Overvad, Kim Tjønneland, Anne Boutron-Ruault, Marie-Christine Mesrine, Sylvie Severi, Gianluca Dossus, Laure Rinaldi, Sabina Boeing, Heiner Benetou, Vassiliki Lagiou, Pagona Trichopoulou, Antonia Krogh, Vittorio Kuhn, Elisabetta Panico, Salvatore Bueno de Mesquita, H. Bas Onland-Moret, N. Charlotte Peeters, Petra H. M. Torhild Gram, Inger Weiderpass, Elisabete Duell, Eric J. Sánchez, María José Ardanaz, Eva Etxezarreta, Nerea Navarro, Carmen Idahl, Annika Lundin, Eva Jirström, Karin Manjer, Jonas Wareham, Nicholas J. Khaw, Kay-Tee Smith-Byrne, Karl Travis, Ruth C. Gunter, Marc J. Merritt, Melissa A. Riboli, Elio Cramer, Daniel W. Kaaks, Rudolf
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Càncer d'ovari Marcadors bioquímics Ovarian cancer Biochemical markers
topic	Càncer d'ovari Marcadors bioquímics Ovarian cancer Biochemical markers
description	Purpose: About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate earlydetection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study. Experimental Design: We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. Results: We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. Conclusions: CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases. (C) 2016 AACR.
publishDate	2016
dc.date.none.fl_str_mv	2016 2018 2018 2018
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion
format	article
status_str	acceptedVersion
dc.identifier.none.fl_str_mv	https://hdl.handle.net/2445/125704
url	https://hdl.handle.net/2445/125704
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	Versió postprint del document publicat a: https://doi.org/10.1158/1078-0432.CCR-16-0316 Clinical Cancer Research, 2016, vol. 22, num. 18, p. 4664-4675 https://doi.org/10.1158/1078-0432.CCR-16-0316
dc.rights.none.fl_str_mv	(c) American Association for Cancer Research, 2016 info:eu-repo/semantics/openAccess
rights_invalid_str_mv	(c) American Association for Cancer Research, 2016
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	23 p. application/pdf
dc.publisher.none.fl_str_mv	American Association for Cancer Research
publisher.none.fl_str_mv	American Association for Cancer Research
dc.source.none.fl_str_mv	Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str	Recercat. Dipósit de la Recerca de Catalunya
collection	Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869422959268986880
score	15,811543

A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort

Similares en LA Referencia